3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
36
Triple Negative Breast Neoplasms
32
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Neoplasm Metastasis
7
Lung Neoplasms
5
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Glioblastoma
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Interventions
Paclitaxel
10
trametinib
9
dabrafenib
9
pembrolizumab
5
lenvatinib
5
fosbretabulin
4
Sorafenib
4
Radiotherapy, Intensity-Modulated
4
Doxorubicin
4
Radiotherapy
3
Cisplatin
3
pazopanib
2
efatutazone
2
combretastatin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Vemurafenib
2
Trastuzumab
2
Taxes
2
Nivolumab
2
Gefitinib
2
Filgrastim
2
Everolimus
2
Docetaxel
2
Carboplatin
2
Bevacizumab
2
zimberelimab
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Carcinoma, Anaplastic
×
sacituzumab govitecan
×
Clear all
NCT06235216
2024-11-01
SETHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2
Recruiting
42 enrolled